glp-1 companies Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating FDA says that the GLP-1

doi: 10.1210/clinem/dgaa891

DDDT Volume 18 , 39253938 (2024)

Review the sources used below for this article: This article references information from the KFF (Kaiser Family Foundation) Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford This article references information from the FDA: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems, Specifically in Adults with Obesity or Overweight This article references information from a recent study published in The New England Journal of Medicine : Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity This article references information from the American College of Cardiology: OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions This article references information from Reuters: Lilly will have supply of new weight loss pill for many countries, exec says

We believe their mechanism of action represents the forefront of modern, effective medical weight management

Like semaglutide, it is administered as a once-weekly subcutaneous injection